Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
about
Novel Therapeutic GPCRs for Psychiatric Disorders.Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania.Update on the role of antipsychotics in the treatment of Tourette syndrome.Antipsychotic Medications and Risk of Acute Coronary Syndrome in Schizophrenia: A Nested Case-Control Study.Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report.Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic reviewAripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression.Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis.Treatment strategies for tics in Tourette syndrome.Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse.Tolerability profile of aripiprazole in patients with Tourette syndrome.Aripiprazole: a review of its use in the management of schizophrenia in adults.Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design.Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.Spontaneous recovery of traumatic brain injury-induced functional deficits is not hindered by daily administration of lorazepam.Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma.Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
P2860
Q30407406-2B36C3F3-7381-40A5-8D66-8CF0C6867DD4Q34529810-AC78BD15-05E7-487F-8D4C-BA8767FEE649Q35839717-C00AA176-62EA-4A1F-A7E1-FE67D0500647Q36140777-61D99E2B-0EBF-44E1-AFAE-D24AFC6F7FEDQ36216477-20A0EABF-7453-41F6-BD96-40543538A461Q36965451-6A533A1C-0DD7-438B-9497-2AAD4D051088Q37052408-C09F5A99-5C81-4A3A-9A11-7B0B6AC540FFQ37299210-D805AF31-EA4A-4364-8231-217EA4F05928Q37724642-2B4DAFA5-215E-4B29-8D2F-F22660DA9EB5Q37810163-F7B46A87-E798-4DA4-9514-6214B9745D2AQ37845661-59C74F18-3E3B-4161-BFAF-0CB85EA330CBQ37855928-AD2E502A-E254-499E-ACB2-DB00DC409183Q37913715-D3A118E7-E313-43E8-8B36-CB0EC3C6AEA7Q37980517-B39F7699-E6A5-47E7-8594-F53867A9CADDQ43213313-DAEDB333-1807-46F8-AE99-FEE6B3E0CFACQ46128379-C03CA427-DEA9-429E-A9FB-19D870ED0BFDQ47371361-6EB4638F-2EDE-4534-AA6F-53A24251C2BAQ48600420-50DE7F95-7B9A-4776-A2C1-5A6705CEA08DQ48713412-F3F8E722-A595-4514-910C-E8923B016D68Q50737699-E12C52DA-47DE-45B5-B418-17879609CBFA
P2860
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
@en
type
label
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
@en
prefLabel
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
@en
P2860
P1476
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
@en
P2093
Charlie Reavill
Martyn Wood
P2860
P304
P356
10.1517/13543784.16.6.771
P407
P577
2007-06-01T00:00:00Z